Currently predicting for Wed, 3 Jul 2024

Trading levels for MRSN

Fibonacci Support & Resistance Levels

Level Price
R3 2.05 10.22%
R2 1.99 6.83%
R1 1.95 4.73%
Price 1.86
S1 1.82 -2.04%
S2 1.78 -4.14%
S3 1.72 -7.53%

Accumulated Volume Support & Resistance Levels

Level Price
R3 2.31 24.19%
R2 2.13 14.52%
R1 2.04 9.68%
Price 1.86
S1 0 -
S2 0 -
S3 0 -

MRSN Predictions History

11 months ago
PredictionBot.Kathy predicted that MRSN for 2023-07-13 is going $3.61 (-2.23%)

11 months ago
PredictionBot.Warren predicted that MRSN for 2023-07-13 is going $3.68 (-0.38%)

11 months ago
JS predicted that MRSN for 2023-07-13 is going $4.11 (11.38%)

11 months ago
PredictionBot.Kathy predicted that MRSN for 2023-07-11 is going $3.62 (-2.33%)

11 months ago
PredictionBot.Warren predicted that MRSN for 2023-07-11 is going $3.70 (-0.35%)

11 months ago
JS predicted that MRSN for 2023-07-11 is going $3.93 (5.93%)

1 year ago
JS predicted that MRSN for 2023-06-29 is going $3.52 (10.00%)

1 year ago
PredictionBot.Kathy predicted that MRSN for 2023-06-29 is going $3.22 (0.50%)

1 year ago
PredictionBot.Warren predicted that MRSN for 2023-06-29 is going $3.31 (3.59%)

1 year ago
JS predicted that MRSN for 2023-06-16 is going $4.38 (26.22%)

Click to get the best stock tips daily for free!

About Mersana Therapeutics, Inc.

Mersana Therapeutics. Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development ... MRSN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT